Kainos Medicines Announces Initiation Of Phase 1 Clinical Study Of KM-819 In The Treatment Of Parkinson's Disease

SEONGNAM, South Korea, Jan. 27, 2017 /PRNewswire-iReach/ -- Kainos Medicine Inc. today announced that it has initiated Phase 1 clinical trials of its Parkinson's Disease drug candidate code-named "KM-819." The Company has now dosed their first human subject with KM-819, an orally active small molecule that is a potentially disease-modifying treatment of Parkinson's Disease. The trial is taking place in South Korea.

This Phase 1 randomized, double-blind, placebo-controlled study is divided into Part A (Single Ascending Dose) and subsequently Part B (Multiple Ascending Dose), and will evaluate the safety, tolerability, and pharmacokinetics as well as various pharmacodynamics markers of KM-819 in healthy volunteers. A total of 48 people will be enrolled in the initial stages of Part A, including 8 elderly.

KM-819 has shown superior efficacy in neuroprotection in cell models, and in dopaminergic neuron protection in the midbrain of various animal models of Parkinson's disease as well as improvement in behavioral tests, suggesting the drug has the potential capability of slowing or stopping the progression of Parkinson's Disease.

Additional trial details and updates can be found at www.clinicaltrials.gov.

KM-819 is a small molecule developed as an inhibitor for FAF1, a proapoptotic protein, designed to target various degenerative diseases. It has shown superior neuroprotective efficacy in Parkinson's disease models, and recently entered into the clinical trial phase, aiming to prove its efficacy in stopping the disease in human patients. The efficacy of KM-819 may be also explored for other degenerative diseases.

About Parkinson's Disease

Parkinson's Disease is a very common disease of the Central Nervous System (CNS),second only to Alzheimer Disease in the number of people diagnosed with an estimated 6 to 10 million patients worldwide, 1 million of whom are in the United States. It is more common in elderly people and affects 2-3% of those aged 65 and over, with an increase expected as the population continues to age. The current standard of care is limited to supportive symptom management with supplemental dopamine or dopamine agonists or analogous mechanisms; a disease modifying treatment is one of the most urgent needs in order to counter the otherwise inevitably growing impact of Parkinson's Disease.

About Kainos Medicine Inc.

Kainos Medicine Inc. Inc. is a clinical stage biotechnology company based in South Korea, focused on the discovery and early development of novel therapeutics for central nervous system diseases, cancer and viral diseases. Kainos has established research to identify promising drug candidates and has successfully initiated clinical studies for several, including KM-819 for Parkinson's Disease.

For more information, please visit www.kainosmedicine.com

Back to news